FDA Approves Novo Nordisk’s Saxenda as a Treatment for Chronic Weight Management


Saxenda is a once-daily compacted GLP-1 agonist which will arrive in a pencil offering around your 3.0 ounce dose. As background, the medication’s active ingredient, liraglutide, is currently available at the type two diabetes medication Victoza in an optimum dose of 1.8 mg. While Victoza induces a little weight reduction in many individuals, the bigger dose of liraglutide at Saxenda aids individuals lose a whole lot more weight. Normally, individuals with Saxenda in clinical trials dropped about 5-7percent of the body fat, even over one in four individuals dropped over 10 percent of the body fat.

Saxenda has been a complex medication to approve, provided that its usage for obesity in a 3.0 mg dose syncs with Victoza’s usage for diabetes to some 1.8 mg dose — Quite simply, many individuals carrying Victoza for type two diabetes would also qualify for applicants to choose Saxenda for weight control. But, saxenda reviews is just qualified for weight control and isn’t expressly approved to treat type 2 diabetes, yet to be obtained with any other GLP-1 agonist (Byetta/Bydureon, Tanzeum, Trulicity, Victoza), or even to stop diabetes. Nevertheless, many individuals with type two diabetes or prediabetes were at the clinical trials such as Saxenda, and also the outcomes in preventing diabetes and improving blood sugar levels were very remarkable. Participants with prediabetes around Saxenda were prone to revert to standard sugar levels (meaning no more diabetes or prediabetes in any way!) Following one year in comparison to those on placebo (69 percent of participants around Saxenda averaging just 33 percent on placebo). The FDA decided to not incorporate this persuasive information in Saxenda’s tag, meaning patients and providers might not know about these advantages. There’s not any doubt that lots of patients who have type 2 diabetes and prediabetes may utilize Saxenda to handle their own fat, with the extra advantage of improved sugar levels. In the end, it is going to be up to health care providers to choose whether to utilize Saxenda or Victoza from overweight/obese individuals with type two diabetes.

Overall, we’re extremely happy to observe this acceptance offer another treatment choice for anyone seeking to control their burden — really, Saxenda marks the fourth such medication approved by the FDA because 2012 (Belviq, Contrave, Qsymia). It’s increasingly tough to handle weight in our hard food surroundings, a variable compounded with an individual biology that interrupts weight reduction. The good thing is an intriguing method to cap off the end of the calendar year, especially after a solid showing from sufferers as well as other obesity urges in the FDA’s Advisory Committee hearing Saxenda back in September (more about this here and under!) .